The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Diurnal Group plc

28 Oct 2022 13:26

RNS Number : 5291E
Barclays PLC
28 October 2022
 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR

MORE

Rule 8.3 of the Takeover Code (the "Code")

1.

KEY INFORMATION

(a)

Full name of discloser:

 

Barclays PLC.

(b)

Owner or controller of interest and short

 

 

positions disclosed, if different from 1(a):

(c)

Name of offeror/offeree in relation to whose

DIURNAL GROUP PLC

 

relevant securities this form relates:

(d)

If an exempt fund manager connected with an

 

 

offeror/offeree, state this and specify identity of

 

offeror/offeree:

(e)

Date position held/dealing undertaken:

27 Oct 2022

(f)

In addition to the company in 1(c) above, is the discloser making

NO

 

 

 

disclosures in respect of any other party to the offer?

 

 

2.

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)

Interests and short positions in the relevant securities of the offeror or offeree

 

 

to which the disclosure relates following the dealing(if any)

 

Class of relevant security:

5p ordinary

 

Interests

Short Positions

 

Number

(%)

Number

(%)

(1)

Relevant securities owned

 

 

 

 

 

and/or controlled:

 

 

2,315,595

1.36%

0

0.00%

(2)

Cash-settled derivatives:

 

 

 

 

 

and/or controlled:

 

 

0

0.00%

2,315,595

1.36%

(3)

Stock-settled derivatives (including options)

 

 

 

 

 

and agreements to purchase/sell:

 

 

0

0.00%

0

0.00%

 

 

 

 

 

 

 

 

 

TOTAL:

 

 

2,315,595

1.36%

2,315,595

1.36%

(b)

Rights to subscribe for new securities (including directors and other executive

 

 

options)

 

 

 

 

 

 

Class of relevant security in relation to

 

 

 

 

which subscription right exists

 

 

 

 

Details, including nature of the rights

 

 

 

 

concerned and relevant percentages:

 

 

 

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

 

 

 

 

 

Class of relevant

Purchase/sale

Number of

Price per unit

security

 

securities

 

5p ordinary

Purchase

2,315,595

0.2747 GBP

 

 

 

 

 

 

 

 

(b)

Cash-settled derivative transactions

 

Class of

Product

Nature of dealing

Number of

Price per

relevant

description

 

reference

unit

security

 

 

securities

 

5p ordinary

SWAP

Short

2,315,595

0.2747 GBP

 

 

 

 

 

 

 

 

(c)

Stock-settled derivative transactions (including options)

 

(i)

Writing, selling, purchasing or varying

 

Class

Product

Writing,

Number

Exercise

Type

Expiry

Option

of

description

purchasing,

of

price

 

date

money

relevant

 

selling,

securities

per unit

 

 

paid/

security

 

varying etc

to which

 

 

 

received

 

 

 

option

 

 

 

per unit

 

 

 

relates

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(ii)

Exercising

 

 

 

 

 

 

Class of relevant

Product description

Exercising/ exercised against

Number of

Exercise price per

security

 

 

securities

unit

 

 

 

 

 

 

 

 

 

 

 

 

 

(d)

Other dealings (including subscribing for new securities)

 

Class of relevant

Nature of Dealings

Details

Price per unit (if

security

 

 

applicable)

 

 

 

 

4.

OTHER INFORMATION

(a)

Indemnity and other dealings arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding,

 

 

formal or informal, relating to relevant securities which may be an inducement to deal

 

 

or refrain from dealing entered into by the exempt principal trader making the disclosure and any party

 

to the offer or any person acting in concert with a party to the offer:

 

 

 

NONE

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between

 

 

the person making the disclosure and any other person relating to:

 

 

(i) the voting rights of any relevant securities under any option; or

 

 

 

(ii) the voting rights of future acquisition or disposal of any relevant securities to which

 

 

any derivative is referenced:

 

 

 

 

 

 

NONE

(c)

Attachments

 

 

 

 

 

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

28 Oct 2022

Contact name:

Large Holdings Regulatory Operations

Telephone number:

020 3134 7213

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETMPBTTMTTTBAT
Date   Source Headline
30th Apr 20193:40 pmRNSHolding(s) in Company
30th Apr 20192:43 pmRNSHolding(s) in Company
26th Apr 20195:52 pmRNSDirector Dealings and Issue of Equity
26th Apr 20193:10 pmRNSHolding(s) in Company
25th Apr 20197:15 amEQSHardman & Co Research: Diurnal Group (DNL): Clarity for Chronocort regulatory pathway
24th Apr 20197:00 amRNSGrant of Orphan Drug Designation in Australia
11th Apr 20197:00 amRNSPositive Scientific Advice from EMA for Chronocort
28th Mar 20197:00 amRNSDiurnal signs marketing and distribution agreement
28th Mar 20197:00 amRNSInterim Results
20th Mar 20197:00 amRNSUpdate on Alkindi US development
25th Feb 20197:00 amRNSSubmission of MAA for Alkindi and Second Patent
11th Feb 201911:00 amRNSNotice of Interim Results
17th Jan 20197:00 amRNSDirector Dealings
16th Jan 20197:15 amEQSHardman & Co Research: Diurnal Group (DNL): Chronocort - seeking regulatory advice
10th Jan 201912:18 pmRNSStatement regarding Price Movement
10th Jan 20197:00 amRNSGrant of second US patent for Chronocort
24th Dec 20187:00 amRNSDirector Dealings and Issue of Equity
12th Dec 20184:02 pmRNSDirector Dealings
11th Dec 20187:00 amRNSRegulatory package for Scientific Advice in Europe
4th Dec 20181:08 pmRNSDirector/PDMR Shareholding
14th Nov 201811:38 amRNSResults of Annual General Meeting
14th Nov 201810:16 amRNSIssue of Equity and Exercise of Options
18th Oct 20187:15 amEQSHardman & Co Research: Diurnal Group (DNL): Unexpected Phase III trial outcome
17th Oct 20187:00 amRNSUpdate on late-stage development pipeline
8th Oct 20184:00 pmRNSPosting of Annual Report and AGM Notice
8th Oct 20182:45 pmRNSSMC Approves The Use of Alkindi
8th Oct 20187:00 amRNSHeadline Data for Chronocort European Phase III
5th Oct 20187:00 amRNSFirst patients enrolled in US Chronocort Phase III
20th Sep 20187:00 amRNSResults for the year ended 30 June 2018
15th Aug 201811:11 amRNSUpdate on Alkindi® in Germany
10th Jul 20181:36 pmRNSDirector/PDMR Shareholding
21st Jun 20187:00 amRNSNotice of Results
18th Jun 20184:54 pmRNSDirector/PDMR Shareholding
18th May 20183:33 pmRNSDirector Dealings
18th May 20181:11 pmRNSAppointment of NOMAD and Joint Broker
15th May 20188:13 amRNSLaunch of Alkindi for paediatric AI in Germany
11th May 20182:41 pmRNSDirector Declaration
17th Apr 20183:58 pmRNSHolding(s) in Company
5th Apr 20182:08 pmRNSDirector/PDMR Shareholding
5th Apr 20188:01 amRNSDirector/PDMR Shareholding
3rd Apr 20182:39 pmRNSResult of GM and Completion of £10.5m Placing
21st Mar 20187:15 amRNSHardman & Co: New capital funds commercial plans
20th Mar 20185:20 pmRNSPlacing Update
14th Mar 20188:47 amRNSProposed Placing
12th Mar 20187:00 amRNSAppointment of CRO to support US Chronocort trials
12th Mar 20187:00 amRNSHalf-year Report
22nd Feb 20187:00 amRNSDiurnal announces grant of first patents in Japan
19th Feb 20187:00 amRNSCommercialisation agreement in Australia and NZ
13th Feb 20187:00 amRNSEuropean marketing authorisation for Alkindi®
12th Feb 20187:00 amRNSCompletion of patient enrolment in EU Phase III

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.